PC3I News
“After over a decade of promise and hype, artificial intelligence (AI) and machine learning (ML) are finally making inroads into clinical practice. AI is defined as a ‘larger umbrella of computer intelligence; a program that can sense, reason, act, and adapt.’ ML is a ‘type of AI that uses algorithms whose performance improves as they are exposed to more data over time.’ From 2017 to 2019, the Food and Drug Administration (FDA) approved or cleared over 40 devices based on AI/ML algorithms for clinical use. Many of these devices improve detection of potential pathology from image-based sources, such as radiographs, electrocardiograms, or biopsies. Increasingly, the FDA has permitted marketing of AI/ML predictive algorithms for clinical use, some of which outperform physician assessment. Despite their promise, AI/ML algorithms have come under scrutiny for inconsistent performance, particularly among minority communities,” writes PC3I Faculty Ravi Parikh with George Maliha, Sara Gerke, and I. Glenn Cohen in a perspective piece in The Millbank Quarterly.
“Algorithm inaccuracy may lead to suboptimal clinical decision-making and adverse patient outcomes. These errors raise concerns over liability for patient injury. Thus far, such concerns have focused on physician malpractice. However, physicians exist as part of an ecosystem that also includes health systems and device manufacturers. Physician liability over use of AI/ML is inextricably linked to the liability of these other actors. Furthermore, the allocation of liability determines not only whether and from whom patients obtain redress, but also whether potentially useful algorithms will make their way into practice: Increasing liability for use or development of algorithms may disincentivize developers and health system leaders from introducing them into clinical practice. We examine the larger ecosystem of AI/ML liability and its role in ensuring both safe implementation and innovation in clinical care.”
Continue reading at The Millbank Quarterly.
Artificial Intelligence and Liability in Medicine: Balancing Safety and Innovation
was authored by George Maliha, MD; Sara Gerke; I. Glenn Cohen; and Ravi Parikh, MD, MPP, FACP, for The Millbank Quarterly.
Related News
PC3I News
Cancer Service Line & PC3I Select 2024 Innovation Accelerator Project
04.22.2024
The Cancer Service Line (CSL) and the Penn Center for Cancer Care Innovation (PC3I) have announced the selection of the 2024 Penn Cancer Innovation Accelerator project. The chosen project, submitted by Katie Boyk, BS, MHA, will identify solutions to improve cancer care scheduling workflows for patients, clinicians, and staff.
PC3I News
PC3I and Tennessee Oncology’s McKay Institute for Oncology Transformation Unveil New Collaborative Relationship
02.06.2024
PC3I and Tennessee Oncology’s McKay Institute for Oncology Transformation announce an academic-community oncology innovation partnership to improve cancer care delivery.
PC3I News
PC3I Leadership Presents at 2023 AORTIC International Conference on Cancer in Africa
12.05.2023
PC3I Associate Director Surbhi Grover and Deputy Director Katharine Rendle presented research at the 14th AORTIC International Conference on Cancer in Africa, which took place in Dakar, Senegal.